Needham & Company Reiterates a 'Buy' Rating on OraSure Technologies (OSUR); National HIV/AIDS Strategy May Expand Testing
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' rating on OraSure Technologies (Nasdaq: OSUR), price target $7.
Needham analyst says, "We expect ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We expect ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
